• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

About FDA

  • Print
  • Share
  • E-mail

Office of Translational Sciences

OTS was established to promote efficient and informative study designs and data analysis methods to quantitatively evaluate the efficacy, safety, and dosing of drugs through collaboration among the Office of Biostatistics, Office of Clinical Pharmacology, and other offices in CDER and Centers in FDA. We foster novel drug development strategies through research and application of statistical and mathematical modeling and simulation techniques in the review and analysis of data in the areas of exposure-response, pharmacokinetics, pharmacodynamics, pharmacogenomics, bioequivalence assessment, clinical trials, quantitative risk assessment, toxicology, and product quality assessment.

Our Mission

 
The Office of Translational Sciences (OTS) promotes and protects public health by assuring that safe and effective drugs are available to Americans by:
  • Developing and applying quantitative and statistical approaches to decision making in the regulatory review process
  • Assuring the validity of clinical trial design and analysis in regulatory decision making
  • Promoting innovation in drug regulatory review across CDER via Critical Path Initiatives
  • Promoting scientific collaboration to advance regulatory review
  • Ensuring alignment of CDER research with CDER goals
 

Office Leadership

 
Director: ShaAvhree Buckman, M.D., Ph.D.                                                                  
Deputy Director: Susan McCune, M.D., M.A.Ed.
 

Contact Us

 
White Oak Building 21 – 4th Floor
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002 Phone: 301-796-2600
Fax: 301-796-9907